The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and long lasting results in young patients. The objective of this randomized open-label study is to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young patients.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St Joseph University, Beirut, Lebanon
• Treatments: Botulinum Toxins

Criteria

Inclusion Criteria:

• female patients presenting to our clinic for Facial wrinkle treatment with botulinum toxin

• Must be between 25-35 years old to be included in group 1.

• Must be older than 45 to be included in groups 2 and 3.

Exclusion Criteria:

• Patients with previous periorbital/forehead surgery

• Patients who plucked the upper eyebrow margin

• Patients with eyebrow tatoos

• Patients with upper face botulinum toxin injection in the past 12 months

• Patients with resorbable upper face fillers injection in the past 12 months

• Patients with previous permanent upper face fillers injection

• Pregnant patients

• Lactating patients

• Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert syndrome)

• Patients using medication that could potentiate the effect of botulinum (ex:

aminoglycoside antibiotics)

• Patients with sensitivity to botulinum toxin or human albumin